• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Keros Therapeutics Inc.

    10/27/25 4:05:30 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KROS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Keros Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    492327101

    (CUSIP Number)


    10/20/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    492327101


    1Names of Reporting Persons

    D. E. Shaw & Co., L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,545,948.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,545,948.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,545,948.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP No.
    492327101


    1Names of Reporting Persons

    D. E. Shaw & Co., L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,537,348.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,537,348.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,537,348.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.0 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    492327101


    1Names of Reporting Persons

    David E. Shaw
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,545,948.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,545,948.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,545,948.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Keros Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    1050 Waltham Street, Suite 302, Lexington, MA 02421
    Item 2. 
    (a)Name of person filing:

    D. E. Shaw & Co., L.P. D. E. Shaw & Co., L.L.C. David E. Shaw
    (b)Address or principal business office or, if none, residence:

    The business address for each reporting person is: Two Manhattan West 375 Ninth Avenue, 52nd Floor New York, NY 10001
    (c)Citizenship:

    D. E. Shaw & Co., L.P. is a limited partnership organized under the laws of the state of Delaware. D. E. Shaw & Co., L.L.C. is a limited liability company organized under the laws of the state of Delaware. David E. Shaw is a citizen of the United States of America.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP No.:

    492327101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    D. E. Shaw & Co., L.P.: 1,545,948 shares This is composed of (i) 1,032,173 shares in the name of D. E. Shaw Valence Portfolios, L.L.C., (ii) 505,175 shares in the name of D. E. Shaw Oculus Portfolios, L.L.C., and (iii) 8,600 shares under the management of D. E. Shaw Investment Management, L.L.C. D. E. Shaw & Co., L.L.C.: 1,537,348 shares This is composed of (i) 1,032,173 shares in the name of D. E. Shaw Valence Portfolios, L.L.C. and (ii) 505,175 shares in the name of D. E. Shaw Oculus Portfolios, L.L.C. David E. Shaw: 1,545,948 shares This is composed of (i) 1,032,173 shares in the name of D. E. Shaw Valence Portfolios, L.L.C., (ii) 505,175 shares in the name of D. E. Shaw Oculus Portfolios, L.L.C., and (iii) 8,600 shares under the management of D. E. Shaw Investment Management, L.L.C. David E. Shaw does not own any shares directly. By virtue of David E. Shaw's position as President and sole shareholder of D. E. Shaw & Co., Inc., which is the general partner of D. E. Shaw & Co., L.P., which in turn is the investment adviser of D. E. Shaw Valence Portfolios, L.L.C. and D. E. Shaw Oculus Portfolios, L.L.C. and the managing member of D. E. Shaw Investment Management, L.L.C., and by virtue of David E. Shaw's position as President and sole shareholder of D. E. Shaw & Co. II, Inc., which is the managing member of D. E. Shaw & Co., L.L.C., which in turn is the manager of D. E. Shaw Valence Portfolios, L.L.C. and D. E. Shaw Oculus Portfolios, L.L.C., David E. Shaw may be deemed to have the shared power to vote or direct the vote of, and the shared power to dispose or direct the disposition of, the 1,545,948 shares as described above constituting 5.1% of the outstanding shares, and, therefore, David E. Shaw may be deemed to be the beneficial owner of such shares. David E. Shaw disclaims beneficial ownership of such 1,545,948 shares.
    (b)Percent of class:

    D. E. Shaw & Co., L.P.: 5.1% D. E. Shaw & Co., L.L.C.: 5.0% David E. Shaw: 5.1%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    D. E. Shaw & Co., L.P.: 0 shares D. E. Shaw & Co., L.L.C.: 0 shares David E. Shaw: 0 shares

     (ii) Shared power to vote or to direct the vote:

    D. E. Shaw & Co., L.P.: 1,545,948 shares D. E. Shaw & Co., L.L.C.: 1,537,348 shares David E. Shaw: 1,545,948 shares

     (iii) Sole power to dispose or to direct the disposition of:

    D. E. Shaw & Co., L.P.: 0 shares D. E. Shaw & Co., L.L.C.: 0 shares David E. Shaw: 0 shares

     (iv) Shared power to dispose or to direct the disposition of:

    D. E. Shaw & Co., L.P.: 1,545,948 shares D. E. Shaw & Co., L.L.C.: 1,537,348 shares David E. Shaw: 1,545,948 shares

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    D. E. Shaw & Co., L.P.
     
    Signature:/s/ Daniel R. Marcus
    Name/Title:Daniel R. Marcus / Chief Compliance Officer
    Date:10/27/2025
     
    D. E. Shaw & Co., L.L.C.
     
    Signature:/s/ Daniel R. Marcus
    Name/Title:Daniel R. Marcus / Authorized Signatory
    Date:10/27/2025
     
    David E. Shaw
     
    Signature:/s/ Daniel R. Marcus
    Name/Title:Daniel R. Marcus / Attorney-in-Fact for David E. Shaw
    Date:10/27/2025

    Comments accompanying signature:  Exhibit 1: Power of Attorney, granted by David E. Shaw relating to D. E. Shaw & Co., Inc., in favor of the signatories hereto, among others, dated August 1, 2024. Exhibit 2: Power of Attorney, granted by David E. Shaw relating to D. E. Shaw & Co. II, Inc., in favor of the signatories hereto, among others, dated August 1, 2024.
    Exhibit Information

    Exhibit 3: Joint Filing Agreement, by and among the Reporting Persons, dated October 27, 2025.

    Get the next $KROS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KROS

    DatePrice TargetRatingAnalyst
    10/20/2025$26.00Overweight
    Wells Fargo
    6/10/2025$18.00Buy → Neutral
    BofA Securities
    1/21/2025Overweight → Neutral
    Cantor Fitzgerald
    1/17/2025$15.00Outperform → Neutral
    Wedbush
    12/16/2024$102.00 → $63.00Outperform
    Oppenheimer
    12/16/2024Buy → Neutral
    Guggenheim
    12/13/2024$100.00 → $47.00Buy
    H.C. Wainwright
    12/12/2024Buy → Hold
    TD Cowen
    More analyst ratings

    $KROS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Keros Therapeutics with a new price target

    Wells Fargo initiated coverage of Keros Therapeutics with a rating of Overweight and set a new price target of $26.00

    10/20/25 8:00:48 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics downgraded by BofA Securities with a new price target

    BofA Securities downgraded Keros Therapeutics from Buy to Neutral and set a new price target of $18.00

    6/10/25 7:53:18 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Keros Therapeutics from Overweight to Neutral

    1/21/25 7:51:46 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    SEC Filings

    View All

    Amendment: SEC Form SC TO-I/A filed by Keros Therapeutics Inc.

    SC TO-I/A - Keros Therapeutics, Inc. (0001664710) (Subject)

    11/20/25 4:10:53 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC TO-I/A filed by Keros Therapeutics Inc.

    SC TO-I/A - Keros Therapeutics, Inc. (0001664710) (Subject)

    11/19/25 6:19:40 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Keros Therapeutics Inc.

    10-Q - Keros Therapeutics, Inc. (0001664710) (Filer)

    11/5/25 4:05:10 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Keros Therapeutics Announces Final Results of Tender Offer

    LEXINGTON, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), today announced the final results of its cash tender offer (the "Tender Offer") to repurchase up to 10,950,165 shares of its common stock, at a fixed purchase price of $17.75 per share, for an aggregate purchase price of up to approximately $194.4 million. The Tender Offer expired at 5:00 p.m. Eastern Time on November 18, 2025. The expiration of the Tender Offer concludes the Company's previously announced $375 million capital return program. Based on the final count by Computershare Trust Company, N.A., the depositary for the Tender Offer (the "Depositary"), a total of 1

    11/20/25 4:01:00 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics Announces Preliminary Results of Tender Offer

    LEXINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), today announced the preliminary results of its cash tender offer (the "Tender Offer") to repurchase up to 10,950,165 shares of its common stock, at a fixed purchase price of $17.75 per share, for an aggregate purchase price of up to approximately $194.4 million. The Tender Offer expired at 5:00 p.m. Eastern Time on November 18, 2025. The expiration of the Tender Offer concludes the Company's previously announced $375 million capital return program. Based on the preliminary count by Computershare Trust Company, N.A., the depositary for the Tender Offer (the "Depositary"),

    11/19/25 6:00:00 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics Reports Third Quarter 2025 Financial Results

    LEXINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today reported financial results for the quarter ended September 30, 2025. "We are excited that our partner Takeda plans to advance elritercept into a Phase 3 clinical trial to evaluate elritercept in the first-line setting in myelodysplastic syndromes," said Jasbir S. Seehra, Ph.D., President and Chief Executiv

    11/5/25 4:01:00 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Adar1 Capital Management, Llc bought $328,127 worth of shares (34,925 units at $9.40) (SEC Form 4)

    4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

    4/11/25 9:57:19 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Pontifax Management 4 G.P. (2015) Ltd. sold $84,975,125 worth of shares (4,787,331 units at $17.75) (SEC Form 4)

    4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

    10/17/25 5:53:28 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Adar1 Capital Management, Llc sold $95,659,436 worth of shares (5,389,264 units at $17.75) (SEC Form 4)

    4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

    10/15/25 1:24:20 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Seehra Jasbir was granted 90,500 shares, increasing direct ownership by 30% to 392,723 units (SEC Form 4)

    4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

    9/5/25 4:10:08 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    Leadership Updates

    Live Leadership Updates

    View All

    Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer

    LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced the appointment of Yung H. Chyung, M.D., as Keros' Chief Medical Officer, effective as of November 1, 2024. "We are thrilled to welcome Yung to Keros and look forward to leveraging his development and TGF-ß superfamily expertise as we continue to advance our clinical programs," said Chair and Chi

    10/16/24 8:00:00 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors

    LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it appointed Jean-Jacques Bienaimé to its Board of Directors, effective June 1, 2024. "On behalf of the Board, we are delighted to welcome Jean-Jacques to Keros during this pivotal phase of our growth," said President and Chief Executive Officer Jasbir Seehra, Ph.D. "Jean-Jacques is a deeply

    5/28/24 4:01:00 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics Appoints Alpna Seth, Ph.D., to its Board of Directors

    LEXINGTON, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that it appointed Alpna Seth, Ph.D., to its Board of Directors, effective May 1, 2023. "Dr. Seth's deep industry experience and expertise in drug development, global operations and product launches will be an invaluable addition to our Board of Directors," said President and Chief Executive Officer Jasbir Seehra, Ph.D. "We a

    4/19/23 8:00:00 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    Financials

    Live finance-specific insights

    View All

    Keros Therapeutics Reports Third Quarter 2025 Financial Results

    LEXINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today reported financial results for the quarter ended September 30, 2025. "We are excited that our partner Takeda plans to advance elritercept into a Phase 3 clinical trial to evaluate elritercept in the first-line setting in myelodysplastic syndromes," said Jasbir S. Seehra, Ph.D., President and Chief Executiv

    11/5/25 4:01:00 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment

    AUSTIN, Texas, Aug. 21, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "we"), the largest stockholder of Keros Therapeutics (NASDAQ:KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today released an open letter to Keros' Board of Directors (the "Board") expressing its disappointment with the Board's refusal to engage with ADAR1 on the Company's strategy, capital allocation priorities and Board refreshment. The full text of the letter is below. Dear Members of the Board: In July, we wrote to the Board privately to propose an in-person meeting to discuss our ideas to maximize stockholder value. We had

    8/21/25 8:30:00 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros to Exclusively Prioritize the Clinical Advancement of KER-065

    Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced a strategic realignment designed to reallocate resources towards the development of its key clinical program, KER-065. As part of thi

    8/6/25 4:15:00 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

    SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

    2/13/24 6:38:35 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

    SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

    2/9/24 9:16:07 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

    SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

    1/26/24 5:26:51 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care